Cellerant Stem Cell Transplantation Process Success in Mice

Cellerant Therapeutics has published the results of a study showing that established autoimmune disease can be reversed or stabilized by the transplantation of purified allogeneic hematopoietic stem cells in a mouse study of lupus.

The study was a trial of Cellerant Therapeutics’ process of purifying hematopoietic (blood-forming) donated adult stem cells and using them in transplantation to treat autoimmune diseases. Subjects that underwent this procedure exhibited improved overall survival and decreased lupus symptoms, according to the company.

Cellerant researchers worked with specialized mice that are prone to an autoimmune condition that closely resembles human SLE. The study found that although the donors and recipients were mis-matched, successful engraftment was achieved and graft-versus-host disease was avoided.

California-based Cellerant is developing hematopoietic stem cells for cancer, genetic blood disorders and autoimmune disease.